Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Krupesh P. Patel"'
Autor:
Simon G. Royce, Matthew Shen, Krupesh P. Patel, Brooke M. Huuskes, Sharon D. Ricardo, Chrishan S. Samuel
Publikováno v:
Stem Cell Research, Vol 15, Iss 3, Pp 495-505 (2015)
This study determined if the anti-fibrotic drug, serelaxin (RLN), could augment human bone marrow-derived mesenchymal stem cell (MSC)-mediated reversal of airway remodeling and airway hyperresponsiveness (AHR) associated with chronic allergic airways
Externí odkaz:
https://doaj.org/article/dc3a77e147934a7fa37f6f554d7cc7de
Autor:
Dennis H. Lau, John W. Finnie, Muayad Alasady, Krupesh P. Patel, Rajiv Mahajan, John P. M. Wood, Jonathan M. Kalman, Prashanthan Sanders, Nicholas J. Shipp, Anthony G. Brooks, Jim Manavis, Chrishan S. Samuel
Publikováno v:
JACC: Clinical Electrophysiology. 7:630-641
Objectives This study sought to evaluate the effect of weight loss on the atrial substrate for atrial fibrillation (AF). Background Whether weight loss can reverse the atrial substrate of ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e36956f5fe6535d34641d448e8ae489
https://doi.org/10.1016/j.jacep.2020.11.015
https://doi.org/10.1016/j.jacep.2020.11.015
Autor:
Rajiv, Mahajan, Dennis H, Lau, Anthony G, Brooks, Nicholas J, Shipp, John P M, Wood, Jim, Manavis, Chrishan S, Samuel, Krupesh P, Patel, John W, Finnie, Muayad, Alasady, Jonathan M, Kalman, Prashanthan, Sanders
Publikováno v:
JACC. Clinical electrophysiology. 7(5)
This study sought to evaluate the effect of weight loss on the atrial substrate for atrial fibrillation (AF).Whether weight loss can reverse the atrial substrate of obesity is not known.Thirty sheep had sustained obesity induced by ad libitum calorie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::326866fabb46d4f7e4c1375c7bec4105
https://pubmed.ncbi.nlm.nih.gov/33640353
https://pubmed.ncbi.nlm.nih.gov/33640353
Publikováno v:
Br J Pharmacol
BACKGROUND AND PURPOSE: There is growing interest in stem cell‐derived exosomes for their therapeutic and regenerative benefits given their manufacturing and regulatory advantages over cell‐based therapies. As existing fibrosis impedes the viabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52ed01cab4837da800dfe648c5c9899
https://europepmc.org/articles/PMC6555854/
https://europepmc.org/articles/PMC6555854/
Publikováno v:
British Journal of Pharmacology. 173:2016-2029
Background and Purpose We evaluated the extent to which individual versus combination treatments that specifically target airway epithelial damage [trefoil factor-2 (TFF2)], airway fibrosis [serelaxin (RLX)] or airway inflammation [dexamethasone (DEX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44ffe7eb16e8ad883f0a1feef4d334d6
https://doi.org/10.1111/bph.13494
https://doi.org/10.1111/bph.13494
Autor:
Matthew Shen, Sharon D. Ricardo, Simon G. Royce, Chrishan S. Samuel, Brooke M. Huuskes, Krupesh P. Patel
Publikováno v:
Stem Cell Research, Vol 15, Iss 3, Pp 495-505 (2015)
This study determined if the anti-fibrotic drug, serelaxin (RLN), could augment human bone marrow-derived mesenchymal stem cell (MSC)-mediated reversal of airway remodeling and airway hyperresponsiveness (AHR) associated with chronic allergic airways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc75f197fd79cbae6240e21ece8bc318
Publikováno v:
Clinical & Experimental Allergy. 44:1399-1408
BACKGROUND: The peptide hormone relaxin plays a key role in the systemic hemodynamic and renovascular adaptive changes that occur during pregnancy, which is linked to its antiremodelling effects. Serelaxin (a recombinant form of human gene-2 relaxin)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0bda1e411ae6599ae108068a4063e17
https://doi.org/10.1111/cea.12391
https://doi.org/10.1111/cea.12391
Publikováno v:
5.1 Airway Pharmacology and Treatment.
The extent to which individual vs combination treatments that specifically targeted epithelial damage (trefoil factor-2, TFF2), fibrosis (serelaxin, RLX) or inflammation (AI; dexamethasone, DEX) reversed the pathogenesis of chronic allergic airways d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9400900ccf9feabcb525f7fa80ae6e05
https://doi.org/10.1183/13993003.congress-2016.pa4891
https://doi.org/10.1183/13993003.congress-2016.pa4891
Autor:
Sharon D. Ricardo, Brooke M. Huuskes, Chrishan S. Samuel, Krupesh P. Patel, Anna M Tominaga, Matthew Shen, Simon G. Royce, Rebecca Lim
Publikováno v:
Clinical science (London, England : 1979). 130(23)
Current asthma therapies primarily target airway inflammation (AI) and suppress episodes of airway hyperresponsiveness (AHR) but fail to treat airway remodelling (AWR), which can develop independently of AI and contribute to irreversible airway obstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41402f6842d7e3a001c3e64d3360c1dd
https://pubmed.ncbi.nlm.nih.gov/27647937
https://pubmed.ncbi.nlm.nih.gov/27647937
Publikováno v:
Laboratory investigation; a journal of technical methods and pathology. 94(12)
Asthma develops from injury to the airways/lungs, stemming from airway inflammation (AI) and airway remodeling (AWR), both contributing to airway hyperresponsiveness (AHR). Airway epithelial damage has been identified as a new etiology of asthma but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b667ae45c40c9a3f9b5905340ad4b34
https://pubmed.ncbi.nlm.nih.gov/25264707
https://pubmed.ncbi.nlm.nih.gov/25264707